Skip to main content
. 2016 May 16;12(1):150–156. doi: 10.3892/ol.2016.4576

Table II.

KRAS mutation statuses detected by each analytical method (n=73).

Parameter Direct sequencing Scorpion-ARMS Pyrosequencing Luminex xMAP
Detected cases (%)   68 (93.2%) 71 (97.3%) 70 (95.9%) 69 (94.5%)
Wild-type KRAS (%) 40 (54.8%) 42 (57.5%) 41 (56.2%) 38 (52.1%)
Mutated KRAS (%) 28 (38.4%) 29 (39.7%) 29 (39.7%) 31 (42.5%)
Undetectable cases (%) 5 (6.8%) 2 (2.7%) 3 (4.1%) 4 (5.5%)

KRAS, Kirsten rat sarcoma viral oncogene homolog.